Powered by

Quellis Biosciences Inc. Announces $17 Million Series A Financing; - Lead program aims to develop next-generation antibody therapy for a rare and life-threatening disease -; - Series A financing led by the Perceptive Xontogeny Venture Fund -

Dec 10, 2019 - Business Wire
Investments-Partnership Announcement

Quellis Biosciences Inc., an emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases, today announced its emergence from stealth operations and that it has closed a $17 million Series A financing led by the Perceptive Xontogeny Venture Fund (PXV Fund).

Quellis was founded in November 2017 by biopharma incubator Viridian LLC with seed financing from Xontogeny LLC. The Series A financing was closed following the successful discover...